Group items tagged

Community pharmacists involved in the Independent Prescribers Pathfinder Programme will be able to generate NHS prescriptions through the NHS Electronic Prescription Service (EPS). NHS England has secured a new clinical system, CLEO SOLO from Cleo Systems, to facilitate this service. The system is being rolled out to 'pathfinder' sites so they can start delivering their proposed prescribing models and pathways. Integrated Care Boards (ICBs) across England have been informed of this development and are asked to provide support and leadership to their sites throughout the programme, which will run until March 2025. NHS England will also conduct a series of webinars with ICBs to discuss the CLEO SOLO rollout. David Webb, Chief Pharmaceutical Officer at NHS England, highlighted that the Pathfinder Programme will enable community pharmacist prescribers at 'pathfinder' sites to issue NHS prescriptions for conditions such as cardiovascular and respiratory diseases. "This will help us develop a framework which will support the commissioning of independent prescribing as part of clinical services in community pharmacy in the future," Webb said.

NHS England will collaborate with "a number of system suppliers" to increase the number of trusts using electronic prescription service (EPS) over the next few years. Nishali Patel, clinical lead for digital medicines at NHS England, announced it during the Clinical Pharmacy Congress, held at the Excel, London, on Friday, 10 May 2024. According to Nishali, at least half of all NHS secondary care trusts could be using EPS by 2026. This digital service allows prescribers to send prescriptions electronically to a patient-nominated pharmacy. It is widely used in primary care, where over 95 per cent of prescriptions are now electronically generated. NHS recently extended the service to secondary care settings.

Scottish Conservative MSP Stephen Kerr has slammed the SNP government for making taxpayers cover the cost of 'free' prescriptions for basic painkillers like paracetamol and ibuprofen on the NHS. An analysis conducted by Kerr, first reported in The Telegraph, revealed that the NHS Scotland pays as much as £8.53 per pack of paracetamol under its free prescription policy. Public Health Scotland data shows that nearly 2.5 million prescriptions for the common painkiller were issued in 2023-24, costing more than £14 million. Including an estimated £7 million to cover the pharmacy "dispensing fee", the total cost equates to £8.53 per prescription. In contrast, paracetamol can be purchased for as little as 37p in supermarkets. Similarly, Kerr's analysis found that ibuprofen-available over the counter for just 39p-cost the NHS £6.87 per prescription. Kerr condemned the costs as "beyond absurd," accusing the SNP of financial mismanagement.

Pharmacies in England will soon be allowed to dispense up to 10 per cent more or less than the quantity prescribed for NHS prescriptions, thanks to the introduction of new original pack dispensing (OPD) rules. These changes are part of regulatory amendments laid on Tuesday, 3 September, and will come into effect over the coming months. The amendments are being made to the National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2024 (PLPS). Starting 1 January 2025, pharmacies will have the option to adjust the prescribed quantity by up to 10 per cent for NHS prescriptions so medicines can be supplied in their original manufacturer's pack. Earlier in October 2023, changes to the Human Medicines Regulations (HMRs) permitted pharmacies to dispense up to 10 per cent more or less than the prescribed quantity for private prescriptions of Prescription Only Medicines (POMs).

The NHS in Suffolk and North East Essex has launched a new campaign to reduce the amount of unused medicines that cost the NHS around £300 million a year. Across the UK, it is estimated that £100 million worth of medicines are returned to pharmacies, with an additional £90 million of unused prescription medicines stored in homes. Through social media, posters, and videos, people are encouraged to return unused prescriptions to pharmacies and avoid stockpiling or throwing them away. Reducing medicines waste not only saves money that can be reinvested into patient care within the NHS, but it's also better for the environment. Tania Farrow, who is leading the campaign on behalf of NHS Suffolk and North East Essex Integrated Care Board (ICB), highlighted that everyone has a part to play in reducing medicines waste.

The National Pharmacy Association (NPA) has raised the alarm that many community pharmacies are facing losses on NHS prescriptions due to the "broken" funding system. An analysis of prescription drug prices by the NPA revealed that pharmacies are being underpaid by the NHS by up to £75 a pack for common medicines, resulting in losses of thousands of pounds each month. The analysis report released today (16 October) shows the government reimburses £18.06 for a 56-tablet pack of Amantadine, a drug used to treat Parkinson's symptoms. However, the market price of the drug is £94.05 per pack, leading to a loss of £75.99 per 56-tablet pack for pharmacies-amounting to a shortfall of over £1 per tablet. In some instances, NHS funding covers only one-fifth of the cost that pharmacies have to pay for medicines, according to new figures from the NPA.

The Royal Pharmaceutical Society in England (RPS) and Community Pharmacy England (CPE) have raised alarm over the impending increase in NHS prescription charges, slated to take effect from May 1, 2024. The RPS, represented by Chair Tase Oputu, condemned the rise, labeling it a "dark day for patients" who will now face nearly £10 per prescription item. Oputu emphasised the disproportionate impact on individuals with low incomes, citing the "relentless annual increases in prescription charges" as exacerbating the affordability crisis in healthcare. " Every day pharmacists are asked by patients who are unable to afford all the items in their prescription which ones they can 'do without'" she said. She further added that the financial barriers to get vital medicines should not be faced by any one and advocated for "the abolition of prescription charges in England, as has been implemented in other parts of the UK".

A massive global technology outage on Friday has disrupted essential services, including healthcare, airlines, banks, and broadcasters worldwide. The outage, attributed to a flawed update from cybersecurity firm CrowdStrike, has also affected the National Health Service (NHS) in the UK, with several hospitals and GP practices losing access to their computer systems. Community pharmacies are also facing significant disruptions. Services such as accessing prescriptions from GPs and medicine deliveries have been affected, causing inconvenience to patients and healthcare providers. An NHS spokesperson said: "The NHS is aware of a global IT outage and an issue with EMIS, an appointment and patient record system, which is causing disruption in the majority of GP practices." The spokesperson assured that the NHS has long-standing measures in place to manage such disruptions, including the use of paper patient records and handwritten prescriptions, and the usual phone systems to contact GPs.

Pharmacies that deliver prescriptions nationwide are set to benefit from new financial support from the Department of Science, Innovation, and Technology funding plan announced earlier this month. In an announcement aimed at improving productivity and public services supported by a share of £32 million, the Department of Science, Innovation and Technology said it is set to make major investments in Artificial Intelligence (AI) technologies, including the mission to "build an NHS which is fit for the future". A Nottingham-based organisation, Anteam, is one of the key beneficiaries of this plan and will be working alongside retailers and the NHS to improve the efficiency of their deliveries using AI algorithms. "This technology will match the delivery needs of retailers and hospitals to existing delivery journeys, unlocking under-utilised capacity, cutting carbon emissions and delivering a better experience for patients," the Department said. Minister of Digital Government and AI, Feryal Clark, emphasised the importance of AI in transforming public services. "AI will deliver real change for working people across the UK - not only growing our economy but improving our public services," she stated.

In a recent report released by the Company Chemists' Association (CCA), data from the NHS Pharmacy First service indicates a substantial uptake and positive impact on patient care just two months after its launch. The CCA's findings shed light on the service's efficacy in meeting patient needs and its potential to alleviate pressure on General Practices (GPs) within the NHS. According to the report, over 90,000 Pharmacy First consultations were conducted solely by CCA members within the initial two-month period. Impressively, 88 per cent of these consultations, totaling 81,627, were deemed eligible for NHS-funded care indicating a significant demand for the service among patients. In the first month, the data revealed that more than 90 per cent of eligible patients received necessary care directly through Pharmacy First, bypassing the need for further referral.

The Royal Pharmaceutical Society (RPS) in England and 19 other organisations have written to health secretary Wes Streeting, calling for a cohesive cross-government strategy to tackle medicine shortages across the UK. The letter stresses the need for actions to build supply chain resilience, support UK manufacturing, improve data connectivity, protect access to life-critical medicines, and reduce duplication across the NHS. As the government works on its 10-Year NHS Plan, the signatories emphasise the importance of ensuring patients' continued access to vital medicines, which are "an investment in their health." They underscore that the strategy would require engagement by the government across the NHS and the whole of the medicines supply chain, including manufacturers, suppliers, health professions, and patients. The letter also highlights that delays in accessing medicines could be reduced by changing legislation to empower community pharmacists to make minor amendments to prescriptions when shortages occur.

NHS England has announced the expansion of Electronic Prescription Service (EPS) to Detained Estate health services in England, starting next month. This means prescribers working in prisons would be able to issue EPS 'To Take Out' (TTO) and urgent prescriptions electronically to community pharmacies, eliminating the need for paper FP10 forms. Currently, around 6,000 of these types of FP10s are issued annually by prisons, according to the NHSBSA. However, with the introduction of EPS, the reliance on this method for supplying medicines to people upon release from prison may change. The NHSE noted that EPS rollout will "significantly improve access to urgent medicines and medicines needed by released patients."

The growing issue of medicine shortages is posing significant challenges for both patients and pharmacy teams across the UK. According to new data from the Office for National Statistics, 20 per cent of adults who used pharmacy prescription services in the last 28 days experienced delays in receiving their medications. The survey, Experiences of NHS healthcare services in England, revealed that over 13 per cent of patients had to return to the same pharmacy at a later time to obtain their prescriptions. Many patients were forced to visit multiple pharmacies or seek alternative services such as a GP or urgent care due to medicine shortages. Pharmacy teams were added with extra burden to manage and resolve these issues. Despite these challenges, 85 per cent of patients expressed satisfaction with pharmacy services, reflecting the dedication and value of pharmacists and pharmacy teams in the community.

Kent and Medway prescribe the highest number of semaglutide, liraglutide and tirzepeptide - drugs that are commonly used for treating type 2 diabetes, weight loss, or both - in the UK, according to recent research by Click Pharmacy. Called GLP-1 agonists, these drugs mimic the effects of the GLP-1 hormone, which is released by the body after eating. This hormone slows digestion, stimulates insulin release, and inhibits glucagon, a hormone that raises blood sugar, making GLP-1 agonists effective treatments for diabetes and weight management. The online pharmacy's research reveals that Kent and Medway prescribed the most of these drugs in the month of June 2024, with 6,326 prescriptions. Other NHS Integrated Care Boards (ICBs) with high prescription rates included: Black Country and West Birmingham (5,019) Hampshire, Southampton, and Isle of Wight (4,960) Birmingham and Solihull (4,775) North Central London (4,528) North East London (3,557) North West London (3,498) Cambridgeshire and Peterborough (2,973) Coventry and Warwickshire (2,912) Norfolk and Waveny (2,575) Brighton and Hove topped the list for prescribing Wegovy, a weight-loss drug containing semaglutide, with 35 prescriptions made out in June alone.

Released on Monday morning, the election manifesto shared by the Liberal Democrats pledges to "strengthen patients' rights" by tackling public health inequalities and providing early access to community services. The Liberal Democrats Party's manifesto promises to address the issues at both the "front and back doors" of the National Health Service (NHS), which the party claims has been plunged into crisis by the Conservatives. Pledging to invest in public health and early access to community services, the party aims to "work towards a fairer and more sustainable long-term funding model for pharmacies and build on the Pharmacy First approach to give patients more accessible routine services and ease the pressure on GPs." The pledge also includes making prescriptions for people with chronic mental health conditions free on the NHS, as part of a wider commitment to review the entire schedule of exemptions for prescription charges.

As whooping cough cases rise sharply across the UK, the NHS has reactivated the serious shortage protocols (SSPs) for clarithromycin - a commonly prescribed antibiotic to treat this bacterial infection. Pharmacy bodies had recently warned that community pharmacies were struggling to obtain source clarithromycin for patients. Two SSPs, covering clarithromycin 125mg/5mL and 250mg/5mL oral suspensions, were reactivated on 22 May 2024, and extended until 21 June 2024. These protocols state that for every 5mL of clarithromycin 125mg/5mL oral suspension, pharmacy contractors must supply 2.5mL of clarithromycin 250mg/5mL oral suspension; and for every 5mL of clarithromycin 250mg/5mL oral suspension, one clarithromycin 250mg tablet must be supplied. The SSPs apply to cross-border prescriptions, both NHS and private.

The latest GP Patient Survey 2024 by the National Health Services (NHS) involving 2.56 million patients has revealed encouraging insights into patient experiences with pharmacy services across England. Along with pharmacies, GPs, and dentistry services were also surveyed highlighting the vital role these services provide in healthcare delivery. Among the key findings, 89.3 per cent of respondents reported utilising at least one pharmacy service in the past year, highlighting the widespread reliance on these facilities. Of those who used pharmacy services, an overwhelming majority of 86.8 per cent expressed satisfaction with their experience. The survey identified 'picking up prescriptions' as the most commonly accessed service, with 75.8 per cent of patients utilising this facility.

Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online pharmacies say, in a sign the US drugmaker is gaining ground on its European rival. Mounjaro is appealing to people because of its greater efficacy, six online pharmacies and two patients told Reuters, showing Novo's first-mover advantage is being challenged in the UK even though some pharmacies sell starter doses for the weekly injection for up to 40 per cent more than Wegovy. "Mounjaro is now vastly outstripping Wegovy," said Chemist4U CEO James O'Loan, who said for the past three to four months, Mounjaro has won about 70 per cent of its sales. Chemist4U and another online seller, Simple Online Pharmacy, estimate that as many as 500,000 people in the UK currently take either Mounjaro or Wegovy via prescriptions from private online pharmacies. Mounjaro, unlike Wegovy, is not available through the National Health Service (NHS) though it likely will be next year. Wegovy is only available through the NHS at specialist obesity clinics and in limited circumstances. There is no public data on prescription numbers but the government said last year it had capacity to treat about 35,000 patients.

Coeliac UK has raised grave concerns about the decision by NHS Leicester, Leicestershire and Rutland Integrated Care Board (ICB) to withdraw gluten free prescriptions for people with a diagnosis of coeliac disease and its potential impact on their health. The charity highlighted the significant additional cost of gluten free staple substitute products, which poses a real challenge to maintaining the gluten free diet, the only treatment for the condition. Coeliac UK noted that 72 per cent of respondents to a recent public consultation disagreed with the ICB's proposal to stop gluten free prescribing, and said it is "deeply concerned" by the potential impact of the decision to proceed with removal of provision. The charity accused the ICB of making no meaningful effort to reduce the impact of this policy change for those on low incomes, despite the additional cost of gluten free food being highlighted by 58 per cent of those who disagreed with the proposal.

Community Pharmacy England (CPE) has notified pharmacy teams that starting 1 August 2024, three Hormone Replacement Therapy (HRT) medicines will be discontinued and will no longer be covered under the NHS HRT Prescription Prepayment Certificate (HRT PPC) scheme. These are Bedol® 2mg tablets, Climanor® 5mg tablets and Clinorette® tablets. Since Climanor® 5mg tablets have been discontinued, Medroxyprogesterone 5mg tablets will also be removed from the HRT PPC list, as this generic product is no longer available as a licensed HRT medicine. The CPE also noted that Provera® 5mg tablets, being an unlicensed HRT medicine, are not covered by the HRT PPC. Pharmacy staff are advised to check the NHS Business Services Authority (NHSBSA) website for the most current list of HRT medicines covered by the HRT PPC. The CPE has updated its HRT PPC medicines list to reflect these changes, which will also be updated in Part XVI of the August 2024 Drug Tariff.